Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring recurrent non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) Stage IIIB or IV Newly diagnosed or recurrent disease Measurable lesions At least 10 mm by spiral CT scan OR At least 20 mm by conventional techniques Previously irradiated lesions are considered measurable provided they progressed or appeared after completion of radiotherapy The following are considered nonmeasurable: Pleural or pericardial effusions Cystic lesions Lymphangitis pulmonis Bony x-ray abnormalities Abnormal scans with nonmeasurable filling defects No symptomatic brain metastasis or CNS involvement by CT scan or MRI PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT no greater than 2 times ULN Renal: Creatinine normal Other: No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell carcinoma that is not likely to recur No history of allergic reactions to diuretics or antiemetics (e.g., 5-HT3 antagonists) used on this study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy or biologic therapy for NSCLC Chemotherapy: No prior chemotherapy for NSCLC No prior platinum-based chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior radiotherapy to potential indicator lesion(s) At least 4 weeks since prior radiotherapy and recovered Surgery: Recovered from prior surgical procedure(s) Other: At least 30 days since prior investigational drug
Sites / Locations
- Tower Hematology Oncology Medical Group
- Medical Oncology Internal Medicine
- Bay Area Tumor Institute
- Medical Oncology Care Associates
- UCSF Cancer Center and Cancer Research Institute
- John Wayne Cancer Institute
- Los Angeles County Harbor-UCLA Medical Center
- Medical Oncology-Hematology Consultants, P.A.
- Washington Cancer Institute
- Veterans Affairs Medical Center - Washington, DC
- University of Florida Health Science Center - Jacksonville
- Watson Clinic
- Ocala Research Institute, Inc
- Ocala Oncology Center
- Saint Alphonsus Regional Medical Center
- Dreyer Medical Clinic
- University of Chicago Cancer Research Center
- Northwest Oncology and Hematology, S.C.
- Rockford Clinic
- Cancer Care Center
- CCOP - Northern Indiana CR Consortium
- Hematology-Oncology Clinic
- University of Minnesota Cancer Center
- Capitol Comprehensive Cancer Care Clinic
- Veterans Affairs Medical Center - Kansas City
- St. John's Mercy Medical Center
- Western Montana Clinic
- Veterans Affairs Medical Center - East Orange
- Brookdale University Hospital and Medical Center
- Interlakes Oncology/Hematology PC
- New York Medical College
- Akron General Medical Center
- Cleveland Clinic Taussig Cancer Center
- North Penn Hospital
- Fox Chase - Temple Cancer Center
- Lone Star Oncology
- Center for Oncology Research and Treatment, Medical City Hospital
- Southwest Cancer Center at University Medical Center
- Baptist Health System Cancer Program
- Cancer Therapy Research Center
- Veterans Affairs Medical Center - Temple
- Arlington-Fairfax Hematology/Oncology, PC